CNK

Cinemark Holdings (CNK) stock rose 12.3% in the past month, outperforming the leisure industry decline of 3.3%. The theater operator benefited from record domestic summer box office results, premium-format expansion (XD, ScreenX, IMAX, D-BOX), growing merchandise sales, and strong loyalty program engagement. CNK trades at a discounted forward sales multiple of 1.21X versus the industry average of 2.37X, with improved 2026 and 2027 EPS estimates supporting a favorable investment outlook.

Cinemark Holdings (CNK) has been highlighted as a compelling growth stock opportunity, earning a Zacks Growth Score of A and Zacks Rank #1 (Strong Buy). The company demonstrates strong fundamentals including projected EPS growth of 139.9% (versus 30.5% industry average), efficient asset utilization with an S/TA ratio of 0.76 (above the 0.65 industry average), and positive earnings estimate revisions with a 3.4% upward surge over the past month.

Zacks highlights three stocks with Rank #1 buy ratings and strong momentum: Nucor Corporation (steel manufacturing) with 8.6% three-month gains and 6.5% earnings estimate increase; Cinemark Holdings (cinema exhibition) with 29.5% three-month gains and 7.3% earnings estimate increase; and Medifast Inc (weight management) with 10.0% three-month gains and 47.2% earnings estimate increase.